Clinical Trials · NCT07357766

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

Name: A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

WithdrawnPhase 3Semaglutide Cagrilintide

Phase: Phase 3
Recruitment status: Withdrawn
Sponsor: Novo Nordisk A/S
Enrollment: 0
Start date: Jun 2026
Locations: 116 sites, 14 countries
Primary endpoint: Relative change in body weight

View Semaglutide compound reference